MS and Demyelinating Disorders

The probability of relapse and disability progression during pregnancy was associated with time when natalizumab was stopped and number of relapses in the year before natalizumab treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

The COViMs website includes FAQs, a sample Case Report Form, and COVID-19 esources and will provide real-time data on patients with multiple sclerosis and other central nervous system demyeliminating diseases who have developed COVID-19.

As the treatment of multiple sclerosis continues to evolve and improve, the proposition of lifetime therapy has come under scrutiny.

The director of the MS Comprehensive Care Center at Stony Brook University discussed the need for more innovative approaches to DMTs and better communication about disease processes from physicians.

Disease-modifying therapies used to treat several immune-mediated disorders in neurology may make patients more susceptible to the novel coronavirus.

The North American Registry for Care and Research in MS reached a major milestone, enrolling its 750 patient in an effort to understand more about the disease course of multiple sclerosis.

Both the Plegridy and Avonex drug labels no longer contain the "Pregnancy Category C" classification with the report of human pregnancy registry data.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 3, 2020.

The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University spoke to the importance of properly communicating with patients with MS as a physician.

The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.

Mayo Clinic is in the forefront of changing practice techniques during the COVID-19 pandemic by using video appointments to reach patients.

NeurologyLive’s parent company, MJH Life Sciences, will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University spoke to the debates around halting and beginning treatment in patients with MS.

The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University discussed the need for more originality in the MS pipeline.

Watch Mitzi J. Williams, MD, lead a discussion of the latest best practice guidance and real-world cases of COVID-19 in patients with multiple sclerosis.

ImStem Biotechnology plans to initiate a phase 1 study of the human embryonic-mesenchymal stem cell agent sometime in 2020. Preclinical data suggest its potential to reduce MS relapses and disability progression, and encourage disease arrest.

Neurology News Network for the week ending March 28.

Although the drug requires no CYP2C9 genotyping or first-dose observation, an up-titration scheme should be used due to the risk of transient cardiac conduction issues.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.

Patients with multiple sclerosis who reported cannabis use noted that it was helpful in relieving pain, as well as other symptoms, such as sleep, depression, anxiety, and/or stress.

Neurology News Network for the week ending March 21, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Barry A. Singer, MD, and Nina Riggins, MD, PhD.

The oral selective S1P1 receptor modulator functionally inhibits S1P activity and reduces circulating lymphocytes.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.

The webinar, a partnership between Women Neurologist's Group (WNG) and NeurologyLive, features the latest updates from CMS on billing and coding for telemedicine visits.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed the current thinking about the challenges of addressing multiple sclerosis in older patients.

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.

Telemedicine has potential to play a key role in diagnosis and testing during the outbreak of COVID-19